Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Operating Income Loss of -$86.82 million for the year ending 2025.
- INOVIO PHARMACEUTICALS, INC. showed an increase of +22.8% in Operating Income Loss from 2024 to 2025.
- This data is from INOVIO PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), INOVIO PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 522.0%.
- Historical annual values: Fiscal year 2025: -$86.82 million | Fiscal year 2024: -$112.40 million | Fiscal year 2023: -$143.94 million | Fiscal year 2022: -$267.57 million | Fiscal year 2021: -$301.22 million | Fiscal year 2020: -$124.08 million | Fiscal year 2019: -$111.11 million | Fiscal year 2018: -$94.09 million | Fiscal year 2017: -$83.64 million | Fiscal year 2016: -$76.24 million | Fiscal year 2015: -$34.28 million | Fiscal year 2014: -$39.50 million | Fiscal year 2013: -$19.54 million | Fiscal year 2012: -$23.49 million | Fiscal year 2011: -$21.64 million | Fiscal year 2010: -$19.22 million | Fiscal year 2009: -$13.96 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: